Smith & Nephew stock holds steady on 2025 revenue and margin gains

Smith & Nephew stock, tied to GB0009223206, is supported by 2025 revenue of $5.81 billion and an adjusted operating profit margin of 17.3%, while the shares were last quoted at 1,061p on 27 July 2026.

2025 revenue reached $5.81 billion

Smith & Nephew reported full-year 2025 revenue of $5.81 billion, up from $5.20 billion in 2024, and said underlying revenue growth was 6.3% for the year. The company also cited an adjusted trading profit of $1.01 billion for 2025, which helped lift the adjusted trading profit margin to 17.3% from 16.7% a year earlier.

That mix matters more than a single quarter because it shows the scale of the group’s orthopedic and sports medicine franchise across a full fiscal year. The comparison is clear: revenue expanded by $610 million year on year, while the margin improved by 0.6 percentage points.

Margin gains from 17.3%

For investors watching Smith & Nephew stock, the margin trend is the cleaner signal than top-line growth alone. A company that can add revenue and still lift its trading margin from 16.7% to 17.3% usually has more room to absorb pricing pressure or product-mix swings.

On the balance-sheet side, Smith & Nephew ended 2025 with net debt of $2.16 billion, compared with $2.12 billion at the end of 2024. Free cash flow came in at $616 million in 2025, and the board proposed a full-year dividend of 42.0 cents per share for 2025.

Orthopedics still drives scale

Smith & Nephew’s product mix still depends heavily on orthopedics, sports medicine, and wound care, with the company’s 2025 report showing that established franchises continue to supply the bulk of revenue. That makes the annual margin improvement especially relevant: it suggests the operating base is carrying more of the growth burden than before.

The 2025 annual report also showed that trading profit improved faster than revenue, a favorable sign for a medtech group that competes on procedure volumes, pricing discipline, and innovation cycles. In a year with $5.81 billion of revenue, a move to $1.01 billion of adjusted trading profit gives the stock a more defensible earnings backdrop than a simple sales headline would.

Shares near 1,061p

Smith & Nephew stock last traded around 1,061p on 27 July 2026, which keeps the market focus on whether the 2025 margin gains can persist into the next reporting cycle. The stock line and the annual numbers point to the same question: can the company keep translating a larger sales base into steadier cash generation and a higher trading margin?